Table 1 Baseline patient characteristics
Study group (n = 188) | Control group (n = 174) | |
|---|---|---|
Country of enrolment, n (%) | ||
Japan | 110 (58.5) | 105 (60.3) |
Korea | 52 (27.7) | 49 (28.2) |
Taiwan | 26 (13.8) | 20 (11.5) |
Age (years) | ||
Median | 55 | 52.5 |
Range | 27–84 | 28–81 |
Body surface area (m2), n (%) | ||
<1.25 | 2 (1.1) | 3 (1.7) |
1.25 to <1.5 | 81 (43.1) | 80 (46.0) |
≥1.5 | 105 (55.9) | 91 (52.3) |
ECOG performance status, n (%) | ||
0 | 141 (75.0) | 136 (78.2) |
1 | 47 (25.0) | 38 (21.8) |
Disease status, n (%) | ||
IVB | 22 (11.7) | 27 (15.5) |
Recurrent | 140 (74.5) | 129 (74.1) |
Persistent | 26 (13.8) | 18 (10.3) |
Histological type, n (%) | ||
Squamous | 138 (73.4) | 132 (75.9) |
Adenosquamous | 8 (4.3) | 7 (4.0) |
Adeno | 37 (19.7) | 32 (18.4) |
Other | 5 (2.7) | 3 (1.7) |
Haemoglobin (g/dL), n (%) | ||
<10.0 | 28 (14.9) | 27 (15.5) |
≥10.0 | 160 (85.1) | 147 (84.5) |
Prior radiotherapy, n (%) | 51 (27.1) | 44 (25.3) |
Prior chemoradiotherapy, n (%) | 113 (60.1) | 100 (57.5) |
Disease in previously irradiated field, n (%) | ||
Present | 97 (51.6) | 91 (52.3) |
Absent | 91 (48.4) | 83 (47.7) |
Previous history of platinum-based therapy, n (%) | ||
Yes | 121 (64.4) | 111 (63.8) |
No | 67 (35.6) | 63 (36.2) |
